The GC-MS temperature program was as follows: 80 °C for 3 min; increased to 280 °C at 30 ... Infrared spectra were acquired on a spectrometer (Vertex 70v FTIR, Bruker, Billerica, MA, USA) using ...

BILLERICA, Mass. (AP) — BILLERICA, Mass. (AP) — Bruker Corp. (BRKR) on Thursday reported fourth-quarter earnings of $13.7 million. The Billerica, Massachusetts-based company said it had profit ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Bruker exceeded both EPS and revenue forecasts for Q4 2024. The company reported a 14.6% year-over-year increase in quarterly revenue. Stock price decreased by 0.77% despite the earnings beat ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

2025 Non-GAAP EPS Guidance: $2.67 to $2.72, representing 11% to 13% growth. Bruker Corp (NASDAQ:BRKR) reported a strong Q4 2024 with a 14.6% year-over-year increase in revenues, reaching $979.6 ...

Bruker (BRKR) reported $979.6 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 14.6%. EPS of $0.76 for the same period compares to $0.70 a year ago.

(3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31 ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...